International Centre for Genetic Engineering and Biotechnology
- Categories:About us
- Time of issue:2021-03-11 17:30:36
The International Centre for Genetic Engineering and Biotechnology China Regional Research Centre (ICGEB China RRC) is a non-profit legal entity jointly established by the International Centre for Genetic Engineering and Biotechnology (ICGEB), China National Center for Biotechnology Development (CNCBD), and China Medical City (CMC). The RRC was established in September 2020. It is located in China Medical City, Taizhou, China. The ICGEB China RRC aims to enhance collaboration among related regions and member countries through science and technology, internationalization and building a high-end, talent training and an innovative centre. For science research, it will focus on the virus (vaccine), biologics (antibody drugs), and in-vitro diagnostics at the first stage. Highlighting technology transfer, research results transformation and industrialization, the RRC and ICGEB will jointly train doctoral students and post-doctoral researchers, organize international scientific activities, and provide scholarships for post-doctoral scientists who collaborate on innovative projects.
The ICGEB is a unique intergovernmental organisation initially established as a special project of UNIDO. Autonomous since 1994, it runs 46 state-of-the-art laboratories, in Trieste, Italy, New Delhi, India and Cape Town, South Africa and forms an interactive network with over 65 Member States. It plays a key role in Biotechnology worldwide for excellence in Research, Training and Technology Transfer to industry to contribute in concrete terms to the achievement of sustainable global development and its operations are aligned to those of the United Nations System.
The CNCBD is an organization established in 1983 with the approval of the State Council. It is affiliated with the China Ministry of Science and Technology. The mission of CNCBD is to develop biotechnology, cultivate new bio-industry, and promote bio-economy; study biotechnology and bio-industry strategies, policies and measures home and abroad; take the responsibility and participate in the revision and formulation of biotechnology and bio-industry development laws, policies, projects and plans; and assume the management of biotechnology programs, bio-safety and bio-resource issues. China has become the official Member State of ICGEB since 1992. The Ministry of Science and Technology is the domestic centralized management body with ICGEB. CNCBD assumes the functions of the ICGEB China branch and liaison office.
The China Medical City is the first national-level life science hi-tech park in China. It is jointly established by the Ministry of Science and Technology, the National Health Commission, the National Medical Products Administration, the National Administration of Traditional Chinese Medicine, and the Jiangsu Provincial Government. Located in Taizhou, an important city of the Yangtze River Delta, it covers a planning area of 30 square kilometres. It is committed to building the largest biomedical industry base with the most integrated industrial chain in China. A batch of characteristic industrial clusters has developed such as vaccines, diagnostic reagents, high-end medical equipment, new chemical drug preparations, and special medical formula foods. By the end of 2020, the CMC has gathered more than 1200 well-known domestic and foreign pharmaceutical companies, including 14 multinational companies such as AstraZeneca, Nestlé, Takeda, Boehringer Ingelheim, and Aurobindo.
International Centre for Genetic Engineering and Biotechnology China Regional Research Centre
ADD: 8th Floor, Block D, No. 8 Taohongjing Road, Medical High-tech Zone, Taizhou City, Jiangsu Province